RAB5c Is the Missing Link in How Immune Cells Kill Aspergillus fumigatus

Macrophages are the front-line soldiers of innate immunity, but the molecular logistics that let them actually destroy pathogens have remained surprisingly murky. A new study published in Science Advances takes a close look at LC3-associated phagocytosis (LAP), a specialized pathway that tags pathogen-containing sacs with autophagy proteins to speed up their destruction, and identifies a previously underappreciated traffic coordinator called RAB5c as an essential organizer of the whole process. The findings are preliminary and come largely from cell-culture and mouse models, but they open a concrete new angle on why some fungal infections spiral out of control.

RAB5c Uniquely Drives LC3 Recruitment to Fungal Phagosomes

The human genome encodes three closely related RAB5 proteins, RAB5a, RAB5b, and RAB5c, all of which help route cargo through early endosomes. When researchers at the lab behind this Science Advances study individually silenced each isoform in macrophages, only RAB5c depletion significantly reduced the lipidation of LC3 on phagosomes, the molecular stamp that marks a phagosome for accelerated maturation. RAB5a and RAB5b knockdowns had no comparable effect. The specificity was striking: despite sharing structural similarity with its paralogs, RAB5c appears to occupy a distinct functional niche that the other two cannot cover.

RAB5c turned out to matter at several consecutive steps. Its depletion reduced recruitment of the scaffolding protein Rubicon (RUBCN) and the class III PI3-kinase complex containing VPS34 and Beclin-1 to phagosomes, which in turn cut phosphatidylinositol 3-phosphate (PI(3)P) production. PI(3)P is the lipid signal that activates the NADPH oxidase NOX2, which generates the reactive oxygen species (ROS) needed to drive the pathway forward. Paradoxically, RAB5c-depleted macrophages actually showed higher overall ROS levels, driven by sustained ERK1/2 activity, but the NOX2 complex on the phagosome itself was destabilized, meaning the right oxidant was no longer in the right place at the right time.

How Defective V-ATPase Assembly Blocks the Killing Machinery

Downstream of ROS, the study traces an elegant relay: phagosomal ROS triggers ionic changes that recruit the V1 subunit of the vacuolar-type proton pump (V-ATPase), and V1 then docks ATG16L1 through the protein's WD repeat-containing C-terminal domain. ATG16L1 in turn recruits the ATG5-ATG12 conjugate, which catalyzes LC3 lipidation directly on the phagosome membrane. Knock out any link in this chain and LC3 tagging fails.

RAB5c controls an earlier step in this relay: the delivery of the transmembrane V0 core of V-ATPase to the phagosome. Live imaging showed that V0-positive organelles physically contact the phagosome membrane in a process disrupted by RAB5c silencing. Critically, lowering ROS in RAB5c-depleted cells did not rescue LC3 lipidation, confirming that the V-ATPase trafficking defect is its own problem, not simply a downstream consequence of oxidant imbalance. The distinction matters because it means correcting ROS levels alone would not be sufficient to restore antifungal killing.

The Atg16l1 Mouse Model Confirms Stakes for Aspergillus Clearance

To test whether the V-ATPase-ATG16L1 axis matters in a living animal, the researchers used mice carrying an Atg16l1ΔWD40 mutation that specifically disrupts noncanonical autophagy, including LAP, while leaving conventional macroautophagy intact. Bone marrow-derived macrophages from these mice showed severely impaired LC3 conjugation and failed to kill Aspergillus fumigatus spores as efficiently as wild-type cells, even though ROS production was unaffected.

When the mice were challenged with a pulmonary A. fumigatus infection, the consequences were substantial: higher fungal loads, A. fumigatus hyphae penetrating the lung parenchyma, elevated albumin suggesting barrier damage, and a surge in proinflammatory cytokines. The fungus itself appears to exploit this vulnerability: A. fumigatus produces a pigment called DHN-melanin that excludes p22phox, a NOX2 component, from phagosomes, effectively blocking the pathway at its oxidant-generation step. LAP is not a luxury response; it is a primary line of defense against this pathogen.

For context, CRISPR-based biosensing research has shown how molecular-level precision tools are increasingly being applied to infectious disease detection, and the mechanistic granularity achieved here reflects that same trend toward dissecting pathways at single-protein resolution. Studies on CRISPR-Cas biosensing methods also illustrate the broader push to turn detailed molecular knowledge of host-pathogen interactions into actionable diagnostics.

Open Questions About RAB5c Recruitment and V0 Trafficking Routes

Several important mechanistic questions remain unresolved, and the authors are direct about them. It is not yet clear whether RAB5c promotes PI(3)P production by recruiting RUBCN to phagosomes or by interacting directly with VPS34. The upstream signal that draws RAB5c itself to phagosomes in the first place, possibly phosphatidylserine clustering on the cytoplasmic leaflet of the phagosomal membrane, has not been formally established. And the precise route by which RAB5c-positive early endosomes deliver V0 components to phagosomes, whether through membrane fusion, tubular contacts, or vesicle transfer, remains to be mapped.

The study also focused primarily on IgG-opsonized beads and A. fumigatus models; whether the same RAB5c-dependent relay governs LAP in response to other pathogens such as Mycobacterium tuberculosis or Salmonella, both of which are known to associate with RAB5c-positive compartments, is an open question worth pursuing. Point-of-care diagnostic obstacles remind us that translating mechanistic findings into clinical tools is rarely straightforward, and the same caution applies here: cell and mouse data are a starting point, not a finish line.

What Comes Next for LAP-Targeted Therapies

The Atg16l1ΔWD40 mouse model provides a clean genetic tool to dissect which cell types contribute most to susceptibility, and future work will likely use conditional knockouts to separate macrophage-intrinsic effects from those in dendritic cells or neutrophils. On the therapeutic side, the identification of RAB5c as a node in V0 trafficking gives researchers a new handle: small molecules that stabilize or enhance RAB5c GTPase activity on phagosomes could, in principle, boost LAP in immunocompromised patients who are most vulnerable to invasive aspergillosis.

Given that emerging CRISPR diagnostics are already moving toward integrating molecular pathway knowledge into rapid testing platforms, the mechanistic blueprint laid out here, a linear chain from RAB5c through PI(3)P, NOX2, ROS, V-ATPase, ATG16L1, and LC3, could eventually inform biomarker strategies for predicting LAP dysfunction in high-risk patients. That is a long road, but the map now has considerably more detail than it did before.

Evidence rating

INVESTIGATIONAL — 71/100

Caveats:

• Funding source not disclosed; independent replication has not been reported.
• Primary experiments conducted in RAW264.7 cell lines and mouse bone marrow-derived macrophages; human clinical relevance is unestablished.
• In vivo data uses a mouse model (Atg16l1ΔWD40); direct translation to human antifungal immunity requires further study.

Cell-based and murine study using RAW264.7 macrophages, bone marrow-derived macrophages, and Atg16l1ΔWD40 mice. Demonstrates mechanistic causality within the RAB5c–V-ATPase–ATG16L1–LAP axis but relies on in vitro knockdown models and a single mouse infection model; human data are absent and independent replication has not yet been reported. Funding was not disclosed.